Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Tumour neoantigen mimicry by microbial species in cancer immunotherapy
Bösch M, Baty F, Rothschild S, Tamm M, Jörger M, Früh M, Brutsche M. Tumour neoantigen mimicry by microbial species in cancer immunotherapy. Br J Cancer 2021; 125:313-323.
Apr 6, 2021Tumour neoantigen mimicry by microbial species in cancer immunotherapy
Apr 6, 2021Br J Cancer 2021; 125:313-323
Bösch Maximilian, Baty Florent, Rothschild Sacha I, Tamm Michael, Jörger Markus, Früh Martin, Brutsche Martin
Pembrolizumab-Associated CD8 Vasculitic Mononeuritis Multiplex in a Patient With Mesothelioma
Baldauf M, Kapauer M, Jörger M, Flatz L, Rodriguez R, Frank S, Felbecker A, Hundsberger T. Pembrolizumab-Associated CD8 Vasculitic Mononeuritis Multiplex in a Patient With Mesothelioma. Neurol Neuroimmunol Neuroinflamm 2021; 8
Apr 6, 2021Pembrolizumab-Associated CD8 Vasculitic Mononeuritis Multiplex in a Patient With Mesothelioma
Apr 6, 2021Neurol Neuroimmunol Neuroinflamm 2021; 8
Baldauf Michaela, Kapauer Monika, Jörger Markus, Flatz Lukas, Rodriguez Regulo, Frank Stephan, Felbecker Ansgar, Hundsberger Thomas
Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study
Johnson M, Rich P, Hung J, Appenzeller C, Sun Z, Maag D, Luo Y, Nickner C, Vajikova A, Komarnitsky P, van der Leest C, Okamoto I, Zvirbule Z, Laktionov K, Helland A, Cho B, Gutierrez V, Colinet B, Lena H, Wolf M, Gottfried M, Bar J. Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study. J Thorac Oncol 2021; 16:1570-1581.
Apr 3, 2021Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage-SCLC: Results From the Phase 3 MERU Study
Apr 3, 2021J Thorac Oncol 2021; 16:1570-1581
Johnson Melissa L, Rich Patricia, Hung Jen-Yu, Appenzeller Christina, Sun Zhaowen, Maag David, Luo Yan, Nickner Caroline, Vajikova Alena, Komarnitsky Philip, van der Leest Cor, Okamoto Isamu, Zvirbule Zanete, Laktionov Konstantin, Helland Aslaug, Cho Byoung Chul, Gutierrez Vanesa, Colinet Benoît, Lena Herve, Wolf Martin, Gottfried Maya, Bar Jair
Radiotherapy for thymic epithelial tumours: a review
Süveg K, Putora P, Jörger M, Iseli T, Fischer G, Ammann K, Glatzer M. Radiotherapy for thymic epithelial tumours: a review. Transl Lung Cancer Res 2021; 10:2088-2100.
Apr 1, 2021Radiotherapy for thymic epithelial tumours: a review
Apr 1, 2021Transl Lung Cancer Res 2021; 10:2088-2100
Süveg Krisztian, Putora Paul Martin, Jörger Markus, Iseli Thomas, Fischer Galina Farina, Ammann Karlheinz, Glatzer Markus
Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial
Filho O, Rugo H, Huober J, Golshan M, Sikov W, von Minckwitz G, Rastogi P, Maag D, Wolmark N, Denkert C, Untch M, O'Shaughnessy J, Stover D, Asad S, Ansell P, Watson M, Loibl S, Geyer C, Bae J, Collier K, Cherian M, Symmans W. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial. JAMA Oncol 2021; 7:603-608.
Apr 1, 2021Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial
Apr 1, 2021JAMA Oncol 2021; 7:603-608
Filho Otto Metzger, Rugo Hope S, Huober Jens, Golshan Mehra, Sikov William M, von Minckwitz Gunter, Rastogi Priya, Maag David, Wolmark Norman, Denkert Carsten, Untch Michael, O'Shaughnessy Joyce, Stover Daniel G, Asad Sarah, Ansell Peter J, Watson Mark, Loibl Sibylle, Geyer Charles E, Bae Junu, Collier Katharine, Cherian Mathew, Symmans W Fraser
Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer
Chic N, Prat A, Huober J, Saura C, Di Cosimo S, Láng I, de Azambuja E, Wang Y, Hilbers F, Fumagalli D, Salgado R, Nuciforo P, Luen S, Loi S. Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer. J Natl Cancer Inst 2021
Mar 31, 2021Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer
Mar 31, 2021J Natl Cancer Inst 2021
Chic Nuria, Prat Aleix, Huober Jens, Saura Cristina, Di Cosimo Serena, Láng István, de Azambuja Evandro, Wang Yingbo, Hilbers Florentine, Fumagalli Debora, Salgado Roberto, Nuciforo Paolo, Luen Stephen J, Loi Sherene
Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials
Villegas S, Huober J, Lederer B, van Mackelenbergh M, Tesch H, Jackisch C, Rezai M, Sinn P, Sinn B, Hackmann J, Kiechle M, Schneeweiss A, Weichert W, Denkert C, Schmitt W, Hanusch C, Nekljudova V, Pfarr N, Engel J, Untch M, Schrodi S, Holms F, Ulmer H, Fasching P, Weber K, Albig C, Heinrichs C, Marme F, Hartmann A, Loibl S. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials. Eur J Cancer 2021; 148:159-170.
Mar 18, 2021Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials
Mar 18, 2021Eur J Cancer 2021; 148:159-170
Villegas Sonia L, Huober Jens, Lederer Bianca, van Mackelenbergh Marion, Tesch Hans, Jackisch Christian, Rezai Mahdi, Sinn Peter, Sinn Bruno V, Hackmann John, Kiechle Marion, Schneeweiss Andreas, Weichert Wilko, Denkert Carsten, Schmitt Wolfgang D, Hanusch Claus, Nekljudova Valentina, Pfarr Nicole, Engel Jutta, Untch Michael, Schrodi Simone, Holms Frank, Ulmer Hans U, Fasching Peter A, Weber Karsten E, Albig Christian, Heinrichs Clemens, Marme Frederik, Hartmann Arndt, Loibl Sibylle
NUTM1-rearranged colorectal sarcoma: a clinicopathologically and genetically distinctive malignant neoplasm with a poor prognosis
Van Treeck B, Halling K, Hornick J, Diebold J, Loupakis F, Fassan M, Rothermundt C, Stevens T, Torres-Mora J, Thangaiah J, Folpe A. NUTM1-rearranged colorectal sarcoma: a clinicopathologically and genetically distinctive malignant neoplasm with a poor prognosis. Mod Pathol 2021
Mar 13, 2021NUTM1-rearranged colorectal sarcoma: a clinicopathologically and genetically distinctive malignant neoplasm with a poor prognosis
Mar 13, 2021Mod Pathol 2021
Van Treeck Benjamin J, Halling Kevin C, Hornick Jason L, Diebold Joachim, Loupakis Fotios, Fassan Matteo, Rothermundt Christian, Stevens Todd M, Torres-Mora Jorge, Thangaiah Judith Jebastin, Folpe Andrew L
Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021
Fankhauser C, Tandstad T, Nicolai N, Nicol D, Leão R, Muilwijk T, Janisch F, Mayor de Castro J, Gremmels H, Fizazi K, Fischer S, Boormans J, Bokemeyer C, Algaba F, Albers P, Oldenburg J, Pilar Laguna M. Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021. Eur Urol 2021; 80:4-6.
Mar 12, 2021Recommendations to Balance Benefits and Risks Of Thromboprophylaxis and to Avoid Central Venous-access Devices During First-line Chemotherapy in Men with Metastatic Germ Cell Tumors: The European Association Of Urology Testicular Cancer Panel Position in 2021
Mar 12, 2021Eur Urol 2021; 80:4-6
Fankhauser Christian Daniel, Tandstad Torgrim, Nicolai Nicola, Nicol David, Leão Ricardo, Muilwijk Tim, Janisch Florian, Mayor de Castro Javier, Gremmels Hendrik, Fizazi Karim, Fischer Stefanie, Boormans Joost L, Bokemeyer Carsten, Algaba Ferran, Albers Peter, Oldenburg Jan, Pilar Laguna M
Screening is associated with lower mastectomy rates in eastern Switzerland beyond stage effects
Herrmann C, Morant R, Walser E, Mousavi M, Thürlimann B. Screening is associated with lower mastectomy rates in eastern Switzerland beyond stage effects. BMC cancer 2021; 21:229.
Mar 6, 2021Screening is associated with lower mastectomy rates in eastern Switzerland beyond stage effects
Mar 6, 2021BMC cancer 2021; 21:229
Herrmann Christian, Morant Rudolf, Walser Esther, Mousavi Mohsen, Thürlimann Beat
Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort
Brune M, Cogliatti S, Ossenkoppele G, Löwenberg B, Rudolf C, Li Q, Passweg J, Mazzuchelli L, Medinger M, Tzankov A, Fehr M, Grobholz R, Stussi G, Lundberg P, Vela V, Heim D, Manz M, Haralambieva E, Pabst T, Banz Y, Bargetzi M, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK). Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort. Ann Hematol 2021; 100:1169-1179.
Mar 2, 2021Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort
Mar 2, 2021Ann Hematol 2021; 100:1169-1179
Brune Magdalena M, Cogliatti Sergio B., Ossenkoppele Gert J, Löwenberg Bob, Rudolf Christina Biaggi, Li Qiyu, Passweg Jakob, Mazzuchelli Luca, Medinger Michael, Tzankov Alexandar, Fehr Martin, Grobholz Rainer, Stussi Georg, Lundberg Pontus, Vela Visar, Heim Dominik, Manz Markus G, Haralambieva Eugenia, Pabst Thomas, Banz Yara, Bargetzi Mario, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK)
Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs
Herbrand A, Hemkens L, Novak U, Moffa G, Jörger M, Hoogkamer A, Diem S, Goldkuhle M, Ewald H, Briel M, Schmitt A, Kasenda B. Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs. JAMA Netw Open 2021; 4:e210380.
Mar 1, 2021Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs
Mar 1, 2021JAMA Netw Open 2021; 4:e210380
Herbrand Amanda Katherina, Hemkens Lars G, Novak Urban, Moffa Giusi, Jörger Markus, Hoogkamer Anouk, Diem Stefan, Goldkuhle Marius, Ewald Hannah, Briel Matthias, Schmitt Andreas M, Kasenda Benjamin
Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study
Stoffel S, Lupatsch J, Schwenkglenks M, Dietrich D, Schär C, Feller A, Anchisi S, von Briel T, Zürrer-Härdi U, Gillessen S, Cathomas R, Thürlimann B, von Moos R, Mark M. Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study. Swiss Med Wkly 2021; 151:w20464.
Mar 1, 2021Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study
Mar 1, 2021Swiss Med Wkly 2021; 151:w20464
Stoffel Sandro Tiziano, Lupatsch Judith E, Schwenkglenks Matthias, Dietrich Daniel, Schär Corinne, Feller Anita, Anchisi Sandro, von Briel Thomas, Zürrer-Härdi Ursina, Gillessen Silke, Cathomas Richard, Thürlimann Beat, von Moos Roger, Mark Michael Thomas
Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
Rugo H, Huober J, García-Sáenz J, Masuda N, Sohn J, Andre V, Barriga S, Cox J, Goetz M. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3. Oncologist 2021; 26:e522.
Mar 1, 2021Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
Mar 1, 2021Oncologist 2021; 26:e522
Rugo Hope S, Huober Jens, García-Sáenz José A, Masuda Norikazu, Sohn Joo Hyuk, Andre Valerie A M, Barriga Susana, Cox Joanne, Goetz Matthew
Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16)
Ribi K, von Moos R, Caspar C, Mannhart M, von Burg P, Blum V, Bohanes P, Anchisi S, von Briel T, Zürrer-Härdi U, Cathomas R, Dietrich D, Schär C, Thürlimann B, Mark M. Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16). BMC cancer 2021; 21:182.
Feb 19, 2021Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16)
Feb 19, 2021BMC cancer 2021; 21:182
Ribi Karin, von Moos Roger, Caspar Clemens B, Mannhart Meinrad, von Burg Philippe, Blum Veronika, Bohanes Pierre, Anchisi Sandro, von Briel Thomas, Zürrer-Härdi Ursina, Cathomas Richard, Dietrich Daniel, Schär Corinne, Thürlimann Beat, Mark Michael
In-depth analysis of the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) - The importance of representation of medical specialty and geographic regions
Pratsinis M, Halabi S, Güsewell S, Gillessen S, Omlin A. In-depth analysis of the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) - The importance of representation of medical specialty and geographic regions. Eur Urol Open Sci 2021; 26:14-17.
Feb 12, 2021In-depth analysis of the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) - The importance of representation of medical specialty and geographic regions
Feb 12, 2021Eur Urol Open Sci 2021; 26:14-17
Pratsinis Manolis, Halabi Susan, Güsewell Sabine, Gillessen Silke, Omlin Aurelius
Contrast-enhanced ultrasound can guide the therapeutic strategy by improving the detection of colorectal liver metastases
Sawatzki M, Gueller U, Güsewell S, Husarik D, Semela D, Brand S. Contrast-enhanced ultrasound can guide the therapeutic strategy by improving the detection of colorectal liver metastases. J Hepatol 2021; 74:419-427.
Feb 12, 2021Contrast-enhanced ultrasound can guide the therapeutic strategy by improving the detection of colorectal liver metastases
Feb 12, 2021J Hepatol 2021; 74:419-427
Sawatzki Mikael, Gueller Ulrich, Güsewell Sabine, Husarik Daniela B., Semela David, Brand Stephan
[Home infusion therapy for Pompe disease: Recommendations for German-speaking countries]
Hahn A, Schlegel T, Ballhausen D, Lagler F, Ziegler A, Wenninger S, Löscher W, Hundsberger T, Boentert M, Lampe C, Schoser B. [Home infusion therapy for Pompe disease: Recommendations for German-speaking countries]. Fortschr Neurol Psychiatr 2021
Feb 9, 2021[Home infusion therapy for Pompe disease: Recommendations for German-speaking countries]
Feb 9, 2021Fortschr Neurol Psychiatr 2021
Hahn Andreas, Schlegel Thomas, Ballhausen Diana, Lagler Florian, Ziegler Andreas, Wenninger Stephan, Löscher Wolfgang, Hundsberger Thomas, Boentert Matthias, Lampe Christina, Schoser Benedikt
Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
Ossenkoppele G, Pabst T, Oosterveld M, Obbergh F, Nijziel M, Moors I, Kooy M, Maertens J, Loosdrecht A, Legdeur M, Poel M, Sinnige H, Spertini O, Norden Y, Stussi G, Westerweel P, Weerdt O, Vellenga E, Vekemans M, Velden W, Tick L, Terpstra W, Lammeren-Venema D, Kuball J, Deeren D, Chalandon Y, Brouwer R, Breems D, Borne P, Biemond B, Bargetzi M, Manz M, Löwenberg B, Efthymiou A, Gjertsen B, Graux C, Klift M, Klein S, Jongen-Lavrencic M, Jie A, Jaspers A, Hoogendoorn M, Hess U, Heim D, Gregor M, Janssen J. Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. Cancers (Basel) 2021; 13
Feb 7, 2021Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
Feb 7, 2021Cancers (Basel) 2021; 13
Ossenkoppele Gert, Pabst Thomas, Oosterveld Margriet, Obbergh Florence van, Nijziel Marten, Moors Ine, Kooy Marinus van Marwijk, Maertens Johan, Loosdrecht Arjan van de, Legdeur Marie-Cecile, Poel Marjolein van der, Sinnige Harm, Spertini Olivier, Norden Yvette van, Stussi Georg, Westerweel Peter, Weerdt Okke de, Vellenga Edo, Vekemans Marie-Christiane, Velden Walter van der, Tick Lidwine, Terpstra Wim, Lammeren-Venema Danielle van, Kuball Jurgen, Deeren Dries, Chalandon Yves, Brouwer Rolf, Breems Dimitri, Borne Peter von dem, Biemond Bart, Bargetzi Mario, Manz Markus, Löwenberg Bob, Efthymiou Anna, Gjertsen Bjørn-Tore, Graux Carlos, Klift Marjolein van der, Klein Saskia, Jongen-Lavrencic Mojca, Jie Asiong, Jaspers Aurelie, Hoogendoorn Mels, Hess Urs, Heim Dominik, Gregor Michael, Janssen Jeroen
Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies
Mueller-Schoell A, Mikus G, Huisinga W, Jörger M, Schwab M, Mürdter T, van Dyk M, Michelet R, Klopp-Schulze L, Kloft C. Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies. Pharmaceuticals (Basel) 2021; 14
Feb 3, 2021Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies
Feb 3, 2021Pharmaceuticals (Basel) 2021; 14
Mueller-Schoell Anna, Mikus Gerd, Huisinga Wilhelm, Jörger Markus, Schwab Matthias, Mürdter Thomas E, van Dyk Madelé, Michelet Robin, Klopp-Schulze Lena, Kloft Charlotte